Compare Intuit Inc. (INTU) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs 10X Genomics Inc — how do they compare? Intuit Inc. trades at $279.58 (market cap $80.37B), while 10X Genomics Inc trades at $42.5 (market cap $5.48B). The key difference: Intuit Inc. is far larger — about 14.7× 10X Genomics Inc's market cap, and Intuit Inc. pays a 1.63% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| INTU | TXG | |
|---|---|---|
Market Cap | $80.37B | $5.48B |
Sector | Technology | Health |
52-Week High | $807.39 | $45.80 |
52-Week Low | $255.07 | $11.34 |
Enterprise Value | $78.83B | $5.02B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $293.82, up 0.94% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. The stock faces headwinds from legal investigations into pricing disclosures, contributing to a 20% drop from 2025 highs, but maintains a consensus analyst price target of $423.11 with 71% buy ratings.
The outlook is mixed: strong revenue growth and AI-driven product expansion support upside, but legal risks and competitive pressures pose significant threats. Investors should weigh the company's solid financials against ongoing litigation and market sentiment shifts for balanced risk-reward assessment.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
